# Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/rituximab-for-treatment-of-membranoproliferative-glomerulonephritis-and-c3/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Michael Rudnicki |
| Citations | 46 |
| DOI | 10.1155/2017/2180508 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | http://downloads.hindawi.com/journals/bmri/2017/2180508.pdf |
| OpenAlex ID | https://openalex.org/W2613289047 |
| PMID | 28573137 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Michael Rudnicki](https://scholariq.org/researchers/michael-rudnicki/)

## Paper journal

- [BioMed Research International](https://scholariq.org/journals/biomed-research-international/)

## Paper primary topic

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)

## Paper topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Amyloidosis: Diagnosis, Treatment, Outcomes](https://scholariq.org/topics/amyloidosis-diagnosis-treatment-outcomes/)
- [Platelet Disorders and Treatments](https://scholariq.org/topics/platelet-disorders-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.